KY-05009(CAT: I017145) is a potent ATP-competitive inhibitor of Traf2- and Nck-interacting kinase (TNIK) with a Ki of 100 nM. By targeting TNIK, KY-05009 exerts pharmacological inhibition of TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma cells. It effectively inhibits the protein expression of TNIK, the transcriptional activity of Wnt target genes, and induces apoptosis in cancer cells. KY-05009 demonstrates promising anti-cancer activity and holds potential for cancer treatment. Furthermore, it inhibits proliferation, induces caspase-dependent apoptosis, and suppresses Wnt signaling-related genes in cancer cells, highlighting its therapeutic implications in cancer therapy and modulation of cellular processes related to tumor progression.
| Catalog Number | I017145 |
| CAS Number | 1228280-29-2 |
| Molecular Formula | C₁₈H₁₆N₄O₂S |
| Purity | 95% |
| Reference | [1]. Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101. |
